Point72 Asset Management L.P. Makes New $581,000 Investment in Autolus Therapeutics plc (NASDAQ:AUTL)

Point72 Asset Management L.P. purchased a new stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 247,089 shares of the company's stock, valued at approximately $581,000. Point72 Asset Management L.P. owned approximately 0.09% of Autolus Therapeutics as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its holdings in Autolus Therapeutics by 146.7% in the 4th quarter. Renaissance Technologies LLC now owns 618,942 shares of the company's stock worth $1,455,000 after purchasing an additional 368,071 shares during the last quarter. Handelsbanken Fonder AB increased its position in Autolus Therapeutics by 30.9% during the fourth quarter. Handelsbanken Fonder AB now owns 73,300 shares of the company's stock worth $172,000 after acquiring an additional 17,300 shares during the period. Legal & General Group Plc raised its position in shares of Autolus Therapeutics by 392.0% during the fourth quarter. Legal & General Group Plc now owns 297,736 shares of the company's stock valued at $697,000 after buying an additional 237,224 shares during the last quarter. Cetera Investment Advisers lifted its stake in shares of Autolus Therapeutics by 169.9% in the fourth quarter. Cetera Investment Advisers now owns 356,222 shares of the company's stock valued at $837,000 after buying an additional 224,222 shares during the period. Finally, Wellington Management Group LLP grew its position in Autolus Therapeutics by 4.6% during the fourth quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company's stock worth $59,562,000 after buying an additional 1,125,454 shares in the last quarter. Institutional investors and hedge funds own 72.83% of the company's stock.

Autolus Therapeutics Stock Up 4.8%

NASDAQ:AUTL traded up $0.08 during trading hours on Wednesday, reaching $1.65. The company had a trading volume of 573,526 shares, compared to its average volume of 1,490,877. The stock has a 50-day moving average of $1.41 and a two-hundred day moving average of $2.04. Autolus Therapeutics plc has a one year low of $1.11 and a one year high of $5.00. The firm has a market capitalization of $437.80 million, a PE ratio of -1.36 and a beta of 1.77.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The firm had revenue of $8.98 million during the quarter, compared to analyst estimates of $1.59 million. As a group, sell-side analysts expect that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on AUTL shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a report on Thursday, April 10th. Truist Financial cut their target price on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Finally, Wells Fargo & Company decreased their price target on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research note on Friday, March 21st. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $9.32.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.